Factor xiii (human)
Package labels
Loading package label images…
Looking up MedlinePlus…
From MedlinePlus, U.S. National Library of Medicine
Dosing in kidney impairment
This label has no separate kidney-impairment dosing section. Check warnings and clinical pharmacology in the full label.
Preparation and administration
Prepare this dose
Your numbers for factor xiii (human). Take vial strength, diluent, and limits from the label below.
Enter a dose to see draw volume, final concentration, and rates.
Preparation and Reconstitution For intravenous use only. Reconstitute, using aseptic techniques, prior to use. Do not use Corifact beyond the expiration date on the vial label and carton. Perform a visual inspection of the reconstituted solution. It should be colorless to slightly yellowish, slightly opalescent, and free from visible particles.
Administer Corifact using aseptic techniques to maintain product sterility. Corifact is for single use only. Contains no preservatives. The product must be used within 4 hours after reconstitution. Do not refrigerate or freeze the reconstituted solution. Discard partially used vials. The procedures below are provided as general guidelines for the preparation and reconstitution of Corifact.
Reconstitute Corifact at room temperature as follows: [See table below.] Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Figure 8
Administration Do not mix Corifact with other medicinal products, and administer Corifact through a separate infusion line. Use aseptic techniques when administering Corifact. Administer Corifact after it has been brought to room temperature. It should be administered by slow intravenous injection at a rate not exceeding 4 mL per minute.
Record the batch number of the product in the patient's medical records every time Corifact is administered to the patient.
| | |
| | |
| | |
| | Fig. 1 |
| | Fig. 2 |
| | Fig. 3 |
| | Fig. 4 |
| | Fig. 5 |
| | Fig. 6 |
| | Fig. 7 |
| | Fig. 8 |
| | |
| | |
| |
Drug interactions
Check interactions
Add the patient's other drugs. Matches come from both FDA labels: by name, drug class, and enzyme or transporter pathway.
- Factor xiii (human)
Contraindications
Corifact is contraindicated in patients with known anaphylactic or severe systemic reactions to human plasma-derived products or to any components in Corifact ( see Description [11] ). Corifact is contraindicated in patients with known anaphylactic or severe systemic reactions to human plasma-derived products or to any components in Corifact ( 4 ).
Safety data
Reported adverse events (FAERS)
Liver injury (LiverTox)
LiverTox has no chapter for factor xiii (human). Check the label's hepatic warnings.
Pregnancy and lactation
Pregnancy
8.1 Pregnancy Pregnancy Category C. Animal reproduction studies have not been conducted with Corifact. Safety and effectiveness in pregnancy have not been established. Corifact should be given to a pregnant woman only if clearly needed ( see WARNINGS AND PRECAUTIONS/Thromboembolic Risk [5.3] ).
Lactation
8.3 Nursing Mothers It is not known whether Corifact is excreted in human milk. Use Corifact only if clearly needed when treating nursing women.
For breastfeeding, also see LactMed (National Library of Medicine), which summarizes milk levels and infant effects.
Supply and cost
Drug shortage status
Recalls (last 24 months)
Therapeutic equivalence (Orange Book)
Price ladder
Not the price at the counterThese are not what a patient pays at the pharmacy counter. They are what pharmacies, health plans, and government buyers pay, before manufacturer rebates. A patient's cost depends on their insurance (copay, coinsurance, or deductible) or the pharmacy's cash price.